Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase 1 clinical trial

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Escudier, Bernard ^a   Dorval, Thierry ^b   Chaput, Nathalie ^a   André, Fabrice ^a   Caby, Marie Pierre ^b   Novault, Sophie ^a   Flament, Caroline ^a   Leboulaire, Christophe ^a   Borg, Christophe ^a   Amigorena, Sebastian ^b   Boccaccio, Catherine ^a   Bonnerot, Christian ^b   Dhellin, Olivier ^c   Movassagh, Mojgan ^a   Piperno, Sophie ^b   Robert, Caroline ^a   Serra, Vincent ^c   Valente, Nancy ^d   Le Pecq, Jean Bernard ^c,d   Spatz, Alain ^a   Lantz, Olivier ^b   Tursz, Thomas ^a   Angevin, Eric ^a   Zitvogel, Laurence ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c Anosys   (France)

^d Anosys Inc   (United States)

Author keywords

Cancer vaccine; Dendritic cells; Exosomes; Immunotherapy; Phase I trial

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; DENDRITIC CELL VACCINE; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA B35 ANTIGEN; HLA DP ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 3; TETANUS TOXOID;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER STAGING; CELL CULTURE; CELL VACUOLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DEPIGMENTATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INJECTION SITE REACTION; LEUKOCYTE; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS POTENTIAL; MONOCYTE; PHASE 1 CLINICAL TRIAL; PHENOTYPE; SIDE EFFECT; SKIN METASTASIS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR CELL;

EID: 18144372419     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-10     Document Type: Article

References (32)

1. Pardoll DM: Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002, 2:227-238.
2. Nestle FO, Banchereau J, Hart D: Dendritic cells: On the move from bench to bedside. Nat Med 2001, 7:761-765.
3. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001, 94:459-473.
4. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999, 104: 173-180.
5. + melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000, 165: 3492-3496.
6. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002, 195:1279-1288.
7. Palucka AK, Dhodapkar MV, Paczesny S, Burkeholder S, Wittkowski KM, Steinman RM, Fay J, Banchereau J: Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 2003, 26:432-439.
8. Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK: Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 2004, 199: 1503-1511.
9. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61:6451-6458.
10. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G: Dendritic cells as vectors for therapy. Cell 2001, 106: 271-274.
11. Ikarashi Y, Mikami R, Bendelac A, Terme M, Chaput N, Terada M, Tursz T, Angevin E, Lemonnier FA, Wakasugi H, Zitvogel L: Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production. J Exp Med 2001, 194:1179-1186.
12. Terme M, Tomasello E, Maruyama K, Crepineau F, Chaput N, Flament C, Marolleau JP, Angevin E, Wagner EF, Salomon B, Lemonnier FA, Wakasugi H, Colonna M, Vivier E, Zitvogel L: IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J Immunol 2004, 172:5957-5966.
13. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S: ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003, 425:397-402.
14. Kleijmeer MJ, Escola JM, UytdeHaag FG, Jakobson E, Griffith JM, Osterhaus AD, Stoorvogel W, Melief CJ, Rabouille C, Geuze HJ: Antigen loading of MHC class I molecules in the endocytic tract. Traffic 2001, 2:124-137.
15. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183:1161-1172.
16. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4:594-600.
17. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000, 113 Pt 19: 3365-3374.
18. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ: Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998, 273:20121-20127.
19. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B: Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 2001, 247:163-174.
20. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L: Exosomes as potent cell-free peptidebased vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004, 172: 2126-2136.
21. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L: Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004, 172:2137-2146.
22. Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB: Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother 2003, 26:440-450.
23. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002, 3:1156-1162.
24. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S: Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001, 166:7309-7318.
25. Thery C, Zitvogel L, Amigorena S: Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002, 2:569-579.
26. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB: Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002, 270:211-226.
27. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T: Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 1994, 56:826-829.
28. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM: Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999, 5:335-341.
29. Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee HG, Keilholz U: Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 1997, 71:932-936.
30. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001, 98:10290-10295.
31. Michael A, Morse JG, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly K: A Phase I Study of Dexosome Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer. J Transl Med 2005, 3: 9.
32. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80: 219-230.